Case Control Study of Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate

Completed

Conditions studied: Toxicity

In brief

The purpose of this study is to examine the genetic contribution to the mechanism of lapaquistat acetate- induced hepatic abnormalities.

Key facts

Study ID

NCT00890448

Run by

Takeda

People needed

66

Starts

2009-05-01

Expected to finish

2010-05-01

Last updated by the study team

2012-05-24

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Has experienced an alanine aminotransferase level greater than or equal to 5 times the upper limit of normal, or concurrent elevation of alanine aminotransferase greater than or equal to 3 times the upper limit of normal and bilirubin greater than or equal to 2 times the upper limit of normal while participating in lapaquistat acetate clinical studies.

You may not qualify if…

• None

Where it is running

• Study site — Jacksonville, Florida, United States
• Study site — Jupiter, Florida, United States
• Study site — Idaho Falls, Idaho, United States
• Study site — Richmond, Virginia, United States
• Study site — Córdoba, Argentina
• Study site — Québec, Canada
• Study site — Sainte-Foy, Canada
• Study site — Santiago, Chile
• Study site — Havírov-Šumbark, Czechia
• Study site — Oulu, Finland
• Study site — Nuremberg, Germany
• Study site — Riga, Latvia
• Study site — Groningen, Netherlands
• Study site — Gdansk, Poland
• Study site — Moscow, Russia
• Study site — Saratov, Russia
• Study site — Žilina, Slovakia
• Study site — Johannesburg, South Africa
• Study site — Glasgow, Scotland, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.